SciClone Pharmaceuticals Fact Sheet

Innovative Products for Major Markets and China

SciClone Pharmaceuticals is a biopharmaceutical company engaged in the development and commercialization of innovative products to treat life-threatening diseases. Our strategy is to in-license product candidates for cancer and infectious diseases, and to develop them for commercialization in the major pharmaceutical markets and China. Over the past decade, we have built a successful commercial operation in China and today our lead product ZADAXIN® (thymalfasin) is one of the largest selling imported drugs in this rapidly growing pharmaceutical market. In the major pharmaceutical markets, we are developing our late-stage clinical compounds, including thymalfasin for malignant melanoma and hepatitis C, RP101 for pancreatic cancer and SCV-07 for viral infectious disease.

Build a Leading Pharmaceutical Business in China

Over the last decade in China, we have built a successful business with extensive importation, distribution, and sales capabilities. Through our dedicated sales force of more than 150 Chinese medical representatives, we have built relationships with physicians and administrators in over 500 hospitals and have a strong presence in liver disease, cancer and infectious disease.

As a result, ZADAXIN is one of the top-selling imported pharmaceutical products in China today. We actively are expanding our clinical development and regulatory capabilities by working with established Contract Research Organizations (CROs) to conduct GCP and ICH-standard clinical trials and file regulatory documents with the Chinese State Food and Drug Administration (SFDA). To further expand our product portfolio, we in-licensed the Chinese marketing rights to DC Bead™, a product for the treatment of liver cancer, and filed a regulatory application with the Chinese SFDA in late 2006.

China is one of the world's fastest growing pharmaceutical markets, forecast to increase 15-20% annually to reach $65 billion by 2015. This growth, combined with an aging population and the deregulation of the healthcare system, create a tremendous opportunity for pharmaceutical companies in China.

Financial Information

For the twelve months ended, December 31,

	2007 Guidance	2006	2005
Product sales	exceed $36,000,000	$32,433,000	$27,842,000
Cost of product sales		6,889,000	4,875,000
Research and development expenses	22,000,000	14,088,000	14,406,000
Net income (loss)	(14,000,000)	727,000[(a)]	(7,713,000)
Diluted net income (loss) per share	($0.31)	$0.02	($0.17)
Cash, cash equivalents & short-term investments (at 12/31)	$26,000,000	$42,592,000[(a)]	$42,256,000
Net cash provided by (used in) in operating activities		$1,720,000[(a)]	($8,019,000)

(a) Includes $8,000,000 from a settlement received in April 2006.

SciClone Stock Information

NASDAQ ticker symbol	SCLN
Share price (11/08/07)	$2.08
52-Week range	$1.69-$4.69
Market capitalization	$95.46 mm
Shares out. (9/30/07)	46.1 mm

Milestones (updated 11/07)

Initiate phase 2 pancreatic cancer trial for RP101	4Q07
Initiate liver cancer trial for DC Bead in China	4Q07
In-license/acquire one new product for China	2007
Initiate phase 3 melanoma registration trial for thymalfasin	1Q08
Report phase 2 HCV data for SCV-07	1Q08
Report phase 3 HCV data for thymalfasin triple therapy trial	2H08

SciClone Pharmaceuticals, Inc.
950 Tower Lane,
Suite 900
Foster City, CA 94404
(650) 358-3456
investorrelations@sciclone.com

www.sciclone.com

Develop a Global Product Portfolio

We are building a global portfolio of product candidates to treat cancer and infectious diseases. Our current product candidates include thymalfasin (ZADAXIN) for the treatment of malignant melanoma and hepatitis C (HCV), RP101 for the treatment of pancreatic cancer and SCV-07 for the treatment of viral infectious disease.

To build on our experience in cancer and infectious disease, we are seeking to in-license additional product candidates. We believe that we are well positioned to in-license products given our proven ability to commercialize products in China, and our ability to use data from clinical trials conducted in China for global filings in the major pharmaceutical markets.

Planning Phase 3 Trial for Lead Product Thymalfasin

SciClone's lead product candidate thymalfasin achieved its primary endpoint in a phase 2 clinical trial treating 488 patients diagnosed with stage IV malignant melanoma, the most advanced form of skin cancer. Based on the positive results from this trial, we intend to meet with the FDA and the EMEA with the current objective of initiating a phase 3 registration trial in the first quarter of 2008.

Results from this phase 2 trial showed that thymalfasin 3.2 mg without interferon in combination with DTIC tripled the overall response rate and extended overall survival by nearly 3 months compared to treatment with dacarbazine (DTIC) and interferon alpha. Importantly, all patients in the thymalfasin treatment arms reported greater overall tumor response and longer median and progression free survival than those in the control arm.

Phase 2 Trial Data (Intent-to-Treat)

Treatment Arm	N=	Overall Tumor Response	Median Survival (months)
DTIC + Interferon alpha (control arm)	97	4.1%	6.6
Thymalfasin (3.2 mg) + DTIC	99	12.1%	9.3
Thymalfasin (1.6 mg) + DTIC + Interferon alpha	97	7.2%	9.3
Thymalfasin (3.2 mg) + DTIC + Interferon alpha	97	10.3%	8.5
Thymalfasin (6.4 mg) + DTIC + Interferon alpha	98	6.1%	10.2

Source: SciClone Pharmaceuticals and Sigma-Tau, phase 2 trial results presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO), June 2007.

Trial Updates

Development Status

Thymalfasin (ZADAXIN)

Phase 2:

Malignant melanoma trial

Next milestone:
Expect to begin phase 3 regulatory registration trial in 1Q08

Phase 3:

Hepatitis C triple therapy trial

Next milestone:
Expect to report phase 3 data in 2H08

RP101

Phase 2:

Pancreatic cancer trial

Next milestone:
Expect to begin phase 2 trial by 4Q07

SCV-07

Phase 2:

Hepatitis C trial

Next milestone:
Expect to report data from phase 2 HCV trial in 1Q08

DC Bead

Regulatory process in China

Next milestone:
Initiate liver cancer trial in 4Q07

NOVEMBER 2007